Share Name Share Symbol Market Type
LAVA Therapeutics NV NASDAQ:LVTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.19 2.64% 7.40 7.04 7.54 7.64 6.9501 7.19 25,177 19:23:57

LAVA Therapeutics Up 7% After Orphan Drug Designation

13/10/2021 7:51pm

Dow Jones News

LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart

From Sep 2021 to Oct 2021

Click Here for more LAVA Therapeutics NV Charts.

By Josh Beckerman


LAVA Therapeutics NV shares were up 7% to $7.70 Wednesday after a potential treatment of chronic lymphocytic leukemia received an orphan drug designation from the U.S. Food and Drug Administration.

The FDA lists the generic name of the potential treatment as immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody.


Write to Josh Beckerman at josh.beckerman@wsj.com


(END) Dow Jones Newswires

October 13, 2021 14:36 ET (18:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year LAVA Therapeutics NV Chart

1 Year LAVA Therapeutics NV Chart

1 Month LAVA Therapeutics NV Chart

1 Month LAVA Therapeutics NV Chart
ADVFN Advertorial
Your Recent History
LAVA Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20211028 18:39:14